Roche has announced new data from the VOYAGER study evaluating the real-world effectiveness, durability and safety of Vabysmo (faricimab) in people with neovascular age-related macular degeneration (nAMD), Diabetic Macular Edema (DME) and Macular Edema following Retinal Vein Occlusion (RVO).

The findings, presented at the EURETINA 2026 Annual Meeting in Vienna, Austria, were consistent with results from Vabysmo’s Phase 3 clinical trials. Across the study cohorts, previously untreated eyes showed improvements in vision and retinal anatomy, while previously treated eyes generally maintained vision alongside anatomical improvements.

In the nAMD and DME cohorts, previously untreated eyes experienced improvements in vision and Central Subfield Thickness (CST) after 12 months of Vabysmo treatment. Previously treated eyes maintained vision while showing improvements in CST over the same period.

The study also reported improvements among people with RVO. In the central/hemi-RVO cohort, both previously untreated and treated eyes showed improvements in vision and CST after six months of treatment. In the branch-RVO cohort, previously untreated eyes showed improvements in vision and CST, while previously treated eyes maintained vision and experienced improvements in CST.

Across all cohorts, the presence of Subretinal Fluid (SRF) and Intraretinal Fluid (IRF) was consistently reduced in both previously untreated and previously treated eyes. In the nAMD and DME cohorts, patients received fewer Vabysmo injections during months seven to 12 compared with the first six months, suggesting that treatment intervals were extended.

The VOYAGER study is a prospective, non-interventional real-world study covering 28 countries and regions across six continents. It includes more than 5,000 patients treated for nAMD, DME or RVO and uses AI and deep-learning algorithms to assess SD-OCT images collected during routine clinical practice.

According to Roche, the new findings support the translation of Vabysmo’s efficacy and safety results from controlled Phase 3 trials into routine clinical settings involving diverse patient populations and treatment histories.

Vabysmo is a bispecific antibody that targets angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), two signalling pathways associated with retinal vascular instability and vision loss. It is approved in more than 100 countries for nAMD and DME and in more than 60 countries for macular edema following RVO.